MK-677
Also known as: Ibutamoren, Nutrobal, L-163,191
Key Facts: MK-677
- Category
- Growth Hormone
- FDA Status
- Not FDA Approved
- Clinical Status
- Investigational - Phase II trials completed
- Administration
- Oral
- Typical Dose
- 10-25 mg daily
- Frequency
- Once daily, often before bed
- Evidence Level
- Human Trials
- Duration
- 8-12 weeks or longer
What to Expect
An orally active growth hormone secretagogue that mimics ghrelin. Not a peptide technically, but frequently discussed alongside GH peptides due to similar effects.
Mechanism of Action
MK-677 binds to ghrelin receptors (GHSR) in the brain, stimulating sustained GH release and increasing IGF-1 levels. Unlike injectable GHRPs, it's orally bioavailable and has a long half-life providing 24-hour GH elevation.
Research Summary
Studies show significant increases in GH and IGF-1 levels, improved sleep quality, and increased lean body mass. Research in elderly shows reversal of diet-induced nitrogen wasting. Long-term studies demonstrate sustained efficacy.
Dosing Information
Typical Dosingⓘ
Community experience
10-25 mg daily
10-50 mg daily
Once daily, often before bed
Oral GH secretagogue. Can cause water retention, increased appetite, and blood sugar issues. Some cycle it, others run year-round.
Research Dosingⓘ
Scientific studies
Doses from research studies
Doses from Studies
Duration
8-12 weeks or longer
Administration
Oral
Timing & Administration
Best Time to Take
Before bed
Once daily, consistently at the same time
Food Recommendation
With or without food
Why This Timing?
MK-677 can cause drowsiness and hunger. Evening dosing minimizes daytime appetite increase and supports sleep-related GH release.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Increased appetite and hunger
- ●Weight gain
- ●Water retention
- ●Insulin resistance
- ●Elevated blood glucose
- ●Anxiety
- ●Risk of heart failure (FDA concern - especially elderly)
- ●NOT FDA approved
References
Related Peptides
Peptides commonly compared with MK-677 or used in similar applications.
Ipamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Growth HormoneCJC-1295
Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Growth HormoneTesamorelin
FDAAn FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. One of the few peptides with FDA approval.
Growth HormoneGHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.
Growth HormoneGHRP-2
Clinical TrialsA synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
Growth HormoneSermorelin
PreclinicalA truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.
Growth HormoneWant updates on MK-677 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.